Clinical trials: Differentiation
Leukemia, Myelodysplastic Syndromes
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00077558
- Testing
- fludarabine phosphate, triapine
- Where
- 4 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Thyroid Cancer
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
The purpose of this study is to determine the effectiveness of two anticancer drugs, everolimus and pasireotide, in patients with thyroid cancer when the cancer is no longer responding to treatment with radioiodine or where it is…
- Trial name
- NCT01270321
- Testing
- Everolimus, Pasireotide, Everolimus and Pasireotide
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emory University
Lymphoma, Follicular, Lymphoma, Small Lymphocytic
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Primary Objectives: To document the efficacy of treatment with autologous lymphoma-derived HSPPC-96 of selected patients with indolent lymphoma.
- Trial name
- NCT00081809
- Testing
- autologous human tumor-derived HSPPC-96
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Agenus Inc.
CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis
Transcriptome and Metabolic Analyses of CHAPLE Disease
CHAPLE syndrome (complement hyperactivation, angiopathic thrombosis, protein losing enteropathy) is a newly discovered genetic disorder, which is caused by deleterious mutations in the CD55 gene.
- Conditions
- CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis, Protein-Losing Enteropathies, Complement Regulatory Factor Defect
- Trial name
- CHAPLEOMIC (NCT03950804)
- Testing
- Eculizumab Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marmara University
Hiv, Transmission Vertical
Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV
Mentor Mothers (MMs) are peer supporters who help pregnant and postpartum women living with HIV (WLHIV) as they receive prevention of mother-to-child transmission of HIV (PMTCT) services in resource-limited settings like Kenya.
- Conditions
- Hiv, Transmission Vertical, Viremia, Adherence, Treatment
- Trial name
- PIE-eMMs (NCT06999928)
- Testing
- Enhanced Mentor Mother Strategy
- Where
- Kenya
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Indiana University
Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
- Trial name
- NCT02592356
- Testing
- Computed Tomography, Dual X-ray Absorptiometry, Physical Examination
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Peutz-Jeghers Syndrome
Poorly Differentiated Adenocarcinoma of the Jejunum in a Patient With Peutz-Jeghers Syndrome: A Case Report
Our study is a case report of one of the rarest risk factor, Peutz-Jeghers syndrome, of small bowel malignancy detected in a patient with poorly differentiated adenocarcinoma of small bowel(jejunum)
- Trial name
- NCT06242457
- Where
- Ethiopia
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Haramaya Unversity
Well-Differentiated Neuroendocrine Tumors (NETs)
Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)
Well differentiated neuroendocrine tumors (NETs) are rare and heterogeneous malignancies that frequently evolve toward advanced or metastatic disease, requiring long-term systemic treatment strategies delivered over multiple…
- Trial name
- SEQUENCE-NET (NCT07890012)
- Testing
- PRO-CSS questionnaire
- Where
- 18 sites in France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Leukemia
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002945
- Testing
- aldesleukin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Roswell Park Cancer Institute
HIV Prevention
Evaluation of a Differentiated Point-of-care Active Case Finding & Management Model to Eliminate Mother-to-Child Transmission of HIV in Malawi
Purpose: To conduct a hybrid effectiveness-implementation stepped-wedge trial to: 1. Estimate the effect of the PAC-Man model, compared to SOC, on the proportion of infants who receive timely EID testing. 2.
- Trial name
- PAC-Man (NCT06493357)
- Testing
- PAC-Man, Standard of Care
- Where
- 3 sites in Malawi
- Volunteers
- 2,426 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Leukemia, Myelodysplastic Syndromes
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005593
- Testing
- carboplatin, fludarabine phosphate, topotecan hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Case Comprehensive Cancer Center
Intestinal Tuberculosis, Pulmonary Tuberculosis
Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease
One aims to devise a method for the screening and differentiation of intestinal tuberculosis and Crohn's Disease. Additionally, one aims to detect and survey multidrug resistant TB.
- Conditions
- Intestinal Tuberculosis, Pulmonary Tuberculosis, Crohn's Disease
- Trial name
- NCT01503099
- Where
- 2 sites in India, Norway
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Lovisenberg Diakonale Hospital
Follicular Thyroid Cancer, Insular Thyroid Cancer
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
This randomized phase II trial studies how well dabrafenib works with or without trametinib in treating patients with recurrent thyroid cancer.
- Conditions
- Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
- Trial name
- NCT01723202
- Testing
- dabrafenib, trametinib
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Bhavana Konda
Leukemia
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00053144
- Testing
- cytarabine, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Delivery of Health Care, HIV Infections
Differentiated Service Delivery (DSD) for People Living with HIV (PLHIV) and Comorbidities
This is an implementation study evaluating differentiated service delivery model for the care of comorbidities for people living with HIV (PLWH).
- Trial name
- NCT06738134
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- Chinese University of Hong Kong
HIV
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in Zambia
With the advent of universal eligibility for HIV treatment ("treat all") and same-day and community-based antiretroviral therapy (ART) initiation, retention in care after a patient has started ART remains the main challenge to…
- Trial name
- PREFER-Zambia (NCT05454852)
- Testing
- Survey, Focus group
- Where
- 2 sites in South Africa, Zambia
- Volunteers
- 771 people
- Sponsor
- Boston University
Autoimmune Hemolytic Anemia
Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.
1. Study the presence of circulating CD4+/CD28 null T lymphocytes in AIHA either Idiopathic or Secondary. 2. Role of CD4+/CD28 null T lymphocytes in monitoring response to therapy in AIHA.
- Trial name
- NCT05711264
- Volunteers
- 46 people
- Sponsor
- Assiut University
Leukemia
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of bone marrow and blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899171
- Testing
- DNA analysis, DNA methylation analysis, RNA analysis
- Volunteers
- 251 people
- Sponsor
- SWOG Cancer Research Network
HIV Infections
Client and Provider Preferences for HIV Care
This study will investigate preferences for HIV care among participants enrolled in the "Study to evaluate the feasibility of Community-based Test and Treat strategies among men who have sex with men and transgender women to…
- Trial name
- NCT03216798
- Testing
- questionnaires survey
- Where
- Thailand
- Volunteers
- 370 people
- Sponsor
- Thai Red Cross AIDS Research Centre
Neuroendocrine Tumors
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium[177Lu] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with…
- Trial name
- NCT05459844
- Testing
- Lutetium[177Lu] Oxodotreotide Injection, Octreotide LAR
- Where
- 23 sites in China
- Volunteers
- 196 people
- Sponsor
- Sinotau Pharmaceutical Group